Shuyuan Yeh
About
Shuyuan Yeh is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics.
According to data from OpenAlex, Shuyuan Yeh has authored 204 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Pulmonary and Respiratory Medicine, 89 papers in Molecular Biology and 60 papers in Genetics. Recurrent topics in Shuyuan Yeh's work include Prostate Cancer Treatment and Research (93 papers), Estrogen and related hormone effects (50 papers) and Hormonal and reproductive studies (49 papers). Shuyuan Yeh is often cited by papers focused on Prostate Cancer Treatment and Research (93 papers), Estrogen and related hormone effects (50 papers) and Hormonal and reproductive studies (49 papers). Shuyuan Yeh collaborates with scholars based in United States, Taiwan and China. Shuyuan Yeh's co-authors include Chawnshang Chang, Hong‐Yo Kang, Hiroshi Miyamoto, Hui‐Kuan Lin, Saleh Altuwaijri, Edward M. Messing, Qingquan Xu, Ruey-Sheng Wang, Henry A. Lardy and Hong‐Chiang Chang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.
In The Last Decade
Shuyuan Yeh
203 papers receiving 14.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shuyuan Yeh United States | 68 | 7.0k | 5.1k | 3.7k | 2.9k | 2.7k | 204 | 14.5k | ||
| Donald J. Tindall United States | 70 | 8.4k 1.2× | 7.0k 1.4× | 3.0k 0.8× | 2.7k 0.9× | 3.3k 1.2× | 206 | 16.1k | ||
| Gail P. Risbridger Australia | 53 | 4.4k 0.6× | 2.9k 0.6× | 2.2k 0.6× | 1.2k 0.4× | 1.6k 0.6× | 272 | 9.7k | ||
| Donald P. McDonnell United States | 88 | 11.6k 1.7× | 2.1k 0.4× | 11.5k 3.1× | 3.5k 1.2× | 3.0k 1.1× | 272 | 23.8k | ||
| Gerhard A. Coetzee United States | 57 | 7.2k 1.0× | 2.4k 0.5× | 3.3k 0.9× | 2.7k 0.9× | 1.8k 0.7× | 182 | 12.5k | ||
| Sebastiano Andò Italy | 63 | 5.5k 0.8× | 910 0.2× | 3.7k 1.0× | 2.4k 0.8× | 1.8k 0.6× | 287 | 12.8k | ||
| Masatoshi Nomura Japan | 48 | 5.9k 0.8× | 2.1k 0.4× | 1.7k 0.5× | 943 0.3× | 826 0.3× | 213 | 11.4k | ||
| Nancy L. Weigel United States | 62 | 6.0k 0.9× | 2.2k 0.4× | 6.2k 1.7× | 1.2k 0.4× | 2.1k 0.8× | 166 | 11.5k | ||
| Zoran Čulig Austria | 61 | 5.5k 0.8× | 5.7k 1.1× | 2.3k 0.6× | 2.9k 1.0× | 2.0k 0.7× | 221 | 11.7k | ||
| Atsushi Mizokami Japan | 49 | 3.4k 0.5× | 3.4k 0.7× | 1.1k 0.3× | 1.4k 0.5× | 1.4k 0.5× | 386 | 8.8k | ||
| Eric W.‐F. Lam United Kingdom | 87 | 15.3k 2.2× | 1.3k 0.3× | 1.7k 0.5× | 4.0k 1.4× | 378 0.1× | 298 | 23.1k |
Countries citing papers authored by Shuyuan Yeh
Since
Specialization
Citations
This map shows the geographic impact of Shuyuan Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuyuan Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuyuan Yeh more than expected).
Fields of papers citing papers by Shuyuan Yeh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shuyuan Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuyuan Yeh. The network helps show where Shuyuan Yeh may publish in the future.
Co-authorship network of co-authors of Shuyuan Yeh
This figure shows the co-authorship network connecting the top 25 collaborators of Shuyuan Yeh. A scholar is included among the top collaborators of Shuyuan Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuyuan Yeh. Shuyuan Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Liu, Qing, Bosen You, Jialin Meng, et al.. (2022). Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Therapy. 29(12). 1988–2000.
2.
He, Miao, Huan Yang, Hangchuan Shi, et al.. (2021). Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling. Cancer Letters. 524. 15–28.
3.
Xiao, Yao, Guodong Liu, Yin Sun, et al.. (2020). Targeting the estrogen receptor alpha (ERα)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion. Oncogene. 39(12). 2493–2508.
4.
Chou, Fu-Ju, Yuhchyau Chen, Hao Tian, et al.. (2020). Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity. Cancer Letters. 495. 100–111.
5.
Chou, Fu-Ju, Yuhchyau Chen, Dong Chen, et al.. (2019). Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. EBioMedicine. 40. 504–516.
6.
Chen, Jinbo, Fu-Ju Chou, Shuyuan Yeh, et al.. (2019). Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene. 39(3). 574–586.
7.
Han, Zhenwei, Yong Zhang, Yin Sun, et al.. (2018). ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma. Cancer Research. 78(10). 2550–2563.
8.
Shi, Liang, Hui Lin, Gonghui Li, et al.. (2016). Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Molecular Cancer Therapeutics. 15(4). 731–742.
9.
Tao, Le, Jianxin Qiu, Ming Jiang, et al.. (2016). Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals. Molecular Cancer Therapeutics. 15(8). 1943–1951.
10.
Shang, Zhiqun, Yanjun Li, Minghao Zhang, et al.. (2015). Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Molecular Cancer Therapeutics. 14(11). 2586–2594.
11.
He, Dalin, Lei Li, Guodong Zhu, et al.. (2014). ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptor–Dependent HIF2α/VEGF Signaling Pathway. Cancer Research. 74(16). 4420–4430.
12.
Wang, Xiaohai, Soo Ok Lee, Shujie Xia, et al.. (2013). Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals. Molecular Cancer Therapeutics. 12(6). 1026–1037.
13.
Chang, Chawnshang, et al.. (2013). Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 33(25). 3225–3234.
14.
Ni, Jing, et al.. (2009). In vitro and In vivo Anticancer Effects of the Novel Vitamin E Ether Analogue RRR -α-Tocopheryloxybutyl Sulfonic Acid in Prostate Cancer. Clinical Cancer Research. 15(3). 898–906.
15.
Tang, Ping, et al.. (2009). Dual expression of α-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of α-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas. Modern Pathology. 22(6). 770–775.
16.
Niu, Yuanjie, Saleh Altuwaijri, Kuo‐Pao Lai, et al.. (2008). Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences. 105(34). 12182–12187.
17.
Niu, Yuanjie, Shuyuan Yeh, Hiroshi Miyamoto, et al.. (2008). Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation. Cancer Research. 68(17). 7110–7119.
18.
Zhang, Yanqing, Yue Yang, Shuyuan Yeh, & Chawnshang Chang. (2004). ARA67/PAT1 Functions as a Repressor To Suppress Androgen Receptor Transactivation. Molecular and Cellular Biology. 24(12). 5635–5635.
19.
Yeh, Shuyuan, Hui‐Kuan Lin, Hong‐Yo Kang, et al.. (1999). From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proceedings of the National Academy of Sciences. 96(10). 5458–5463.
20.
Yeh, Shuyuan, Hong‐Chiang Chang, Hiroshi Miyamoto, et al.. (1999). Differential Induction of the Androgen Receptor Transcriptional Activity by Selective Androgen Receptor Coactivators.. The Keio Journal of Medicine. 48(2). 87–92.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Donald J. Tindall Breakdown of academic impact, for papers by Gail P. Risbridger Breakdown of academic impact, for papers by Donald P. McDonnell Breakdown of academic impact, for papers by Gerhard A. Coetzee Breakdown of academic impact, for papers by Sebastiano Andò Breakdown of academic impact, for papers by Masatoshi Nomura Breakdown of academic impact, for papers by Nancy L. Weigel Breakdown of academic impact, for papers by Zoran Čulig Breakdown of academic impact, for papers by Atsushi Mizokami Breakdown of academic impact, for papers by Eric W.‐F. Lam